By Bhanvi Satija LONDON, Jan 7 (Reuters) - GSK will use promising results from two studies of its experimental chronic ...
Please provide your email address to receive an email when new articles are posted on . AASLD and IDSA issued new guidance that opens the opportunity for HBV treatment to more people. The new ...
InvestorsHub on MSN
Aligos Therapeutics edges higher after update on Phase 2 HBV trial
Shares of Aligos Therapeutics Inc (NASDAQ:ALGS) rose 3.1% on Wednesday after the company provided a progress update on its ...
"Our findings underscore the critical role of epigenetic mechanisms in HBV pathogenesis. By targeting these pathways, we can develop therapies that not only suppress viral replication but also offer a ...
(Yicai) Jan. 21 -- Chinese innovative pharmaceutical company Kawin Technology plummeted today after withdrawing its ...
Please provide your email address to receive an email when new articles are posted on . The cumulative probability of functional cure was 14.53% at a mean age of 25.75 years. The annual cure rate was ...
-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...
Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2025 Virion Therapeutics, LLC, a ...
Particularities of the HBV cycle that favour the development of chronic infection (centre), the clinical challenges stemming from these biological characteristics (top) and the opportunities currently ...
ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...
The World Health Organization has issued its first-ever hepatitis B guidelines that outline how to determine who needs treatment, what medicines to use and how to monitor patients long-term. The ...
A new 10-year regional study reveals that adults living with both HIV and hepatitis B virus across the Asia-Pacific face ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results